BioSpace News Archive

Emergex Vaccines Holding Limited announced that Emergex has received its Manufacturing and Import Authorisation Investigational Medicinal Product from the UK’s Medicines and Healthcare Products Regulatory Agency to advance its novel T cell-priming vaccine candidates into clinical production.

Belharra Therapeutics, a next-generation chemoproteomics company transforming small molecule drug discovery by illuminating binding pockets on elusive, high-value drug targets across the proteome, today announced a strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases.

Zentalis ® Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors.

Nanoscope Therapeutics Inc. today announced that management will participate in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, being held virtually on June 25-26, 2024.

Ability Biologics announced the final closing of its seed funding, raising a total of $18 million (US), a financing round led by founding investor Amplitude Ventures.

Remix Therapeutics today announced the appointment of Maria Koehler, M.D., Ph.D., as an independent director to Remix’s Board of Directors.

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc.

Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease.

Roundtable Session to Focus on Multiomic Immune Biomarker Strategies for Optimizing Drug Development and Patient Outcomes.

On June 14-15, SAPA-GP held the 2024 @Philly Cell and Gene Therapy Annual Conference at the Sheraton Valley Forge Hotel in King of Prussia, northwest of Philadelphia.